- Home
- TEI vs DRTS Comparison
TEI vs DRTS Comparison
Compare TEI & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- DRTS
- Stock Information
- Founded
- TEI 1993
- DRTS 2015
- Country
- TEI United States
- DRTS Israel
- Employees
- TEI N/A
- DRTS N/A
- Industry
- TEI Finance Companies
- DRTS Medical/Dental Instruments
- Sector
- TEI Finance
- DRTS Health Care
- Exchange
- TEI Nasdaq
- DRTS Nasdaq
- Market Cap
- TEI 256.5M
- DRTS 211.7M
- IPO Year
- TEI N/A
- DRTS N/A
- Fundamental
- Price
- TEI $5.13
- DRTS $2.57
- Analyst Decision
- TEI
- DRTS Strong Buy
- Analyst Count
- TEI 0
- DRTS 2
- Target Price
- TEI N/A
- DRTS $8.00
- AVG Volume (30 Days)
- TEI 142.4K
- DRTS 28.0K
- Earning Date
- TEI 01-01-0001
- DRTS 05-19-2025
- Dividend Yield
- TEI 10.51%
- DRTS N/A
- EPS Growth
- TEI N/A
- DRTS N/A
- EPS
- TEI N/A
- DRTS N/A
- Revenue
- TEI N/A
- DRTS N/A
- Revenue This Year
- TEI N/A
- DRTS N/A
- Revenue Next Year
- TEI N/A
- DRTS N/A
- P/E Ratio
- TEI N/A
- DRTS N/A
- Revenue Growth
- TEI N/A
- DRTS N/A
- 52 Week Low
- TEI $4.35
- DRTS $1.75
- 52 Week High
- TEI $5.39
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- TEI 44.18
- DRTS 46.76
- Support Level
- TEI $4.78
- DRTS $2.52
- Resistance Level
- TEI $5.20
- DRTS $2.61
- Average True Range (ATR)
- TEI 0.13
- DRTS 0.11
- MACD
- TEI -0.01
- DRTS 0.02
- Stochastic Oscillator
- TEI 50.72
- DRTS 87.10
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments and Money Market Funds.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.